Curis And Autolus Rise On EHA Abstract Data
Potential Advances In AML and NHL
Executive Summary
Promising early-stage data from two companies looking to break into crowded hemato-oncology markets.
You may also be interested in...
BMS Touts Breyanzi's Outpatient Administration As EU Approval Beckons
The US major won a positive opinion from the EU CHMP for Breyanzi with hopes the advantage of outpatient administration could help combat the lack of market impetus for CAR-T therapies.
Next-Gen CAR T & Novel SMA Drug Among New Entrants On EMA’s PRIME
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.